Episódios
-
Study compared the prognostic impact of differing high-risk inclusion criteria used in the monarchE and NATALEE trials among patients with hormone receptor-positive/HER2-negative early #BreastCancer , using data from the MIG1, GIM2, and GIM3 trials. Patients were stratified into high- and low-risk cohorts per each trial’s criteria, and further grouped into concordant low-risk, discordant risk, and concordant high-risk categories.
Link to Article
https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette -
Oncology here & now
In this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.
Join Us
-
Estão a faltar episódios?
-
Dear Colleagues,
Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:
Prognostic implications of risk definitions from the monarchE and NATALEE trial
https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette
Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer
https://link.springer.com/article/10.1007/s10549-025-07685-8?utm_content=buffer1d9c4&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial
https://www.nature.com/articles/s41591-025-03579-w
Assessment of a Polygenic Risk Score in Screening for Prostate Cancer (BARCODE1)
https://nejm.org/doi/full/10.1056/NEJMoa2407934
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer
https://www.nature.com/articles/s41467-025-58435-9
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
https://www.annalsofoncology.org/article/S0923-7534(25)00130-9/abstract
-
Dr. van der Wilk dives into the results of the SANO Trial in Oesophageal Cancer and recently published on the Lancet Oncology.
The phase 3 trial investigated whether active surveillance could be a non-inferior alternative to standard surgery in individuals with oesophageal cancer who achieved a clinical complete response after neoadjuvant chemoradiotherapy. Conducted in 12 Dutch hospitals, the study randomized 309 participants to either active surveillance or standard oesophagectomy. After a median follow-up of 38 months, the 2-year overall survival for active surveillance (74%) was non-inferior to that of standard surgery (71%), with no significant differences in postoperative complications or mortality between groups. These results suggest active surveillance could be a viable option for patient counseling and shared decision-making, although extended follow-up is needed to assess long-term efficacy.
-
The phase 3 LITESPARK-005 trial evaluated patient-reported outcomes (PROs) for belzutifan, a HIF-2α inhibitor, versus everolimus in patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy.
-
Oncology Here & Now
In this interview, OncoAlert faculty members Dr. Joseph McCollom from Parkview Health (USA) and Dr. Cristiane Bergerot from OncoClinicas (Brazil) explore supportive care and the future of telemedicine. Their discussion spans the evolution of telehealth—from its pivotal role during the pandemic to its current applications—and what lies ahead.
Join us for this insightful conversation!
-
Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group @SCLCSMASHERS
, offer new support for patients with this historically stigmatized disease.
Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA -
Oncology Here & Now
In this interview, Dr. Elisa Agostinetto from the Jules Bordet Institute in Belgium speaks with Dr. Maryam Lustberg from Yale Cancer Center. Together, they dive deep into the use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer. Their discussion covers the use of Abemaciclib and Ribociclib following the monarchE and NATALEE trials, applications in the treatment of male breast cancer, and much more.
Join us!
-
In this interview with Dr. Silke Gillessen & Dr. Aurelius Omlin , we delve into the origins, Topics and evolution of the Advanced #ProstateCancer Consensus Conference
@APCCC_Lugano
began in 2015 to address critical questions in prostate cancer management where evidence is lacking or conflicting. Over the years, the conference has focused on various evolving topics, such as oligometastatic disease, treatment sequencing, and new imaging technologies.
The 2024 APCCC highlighted major discussions on next-generation imaging, genomic biomarkers, and diagnostic challenges, with a strong emphasis on the need to balance cutting-edge technology with clinical practicality.
Looking ahead to APCCC 2026, the event will continue to address key issues, including the risk of overtreatment, international disparities in imaging access, and the integration of comorbidities into treatment decision-making. With a welcoming atmosphere, APCCC invites healthcare professionals worldwide to engage in these important discussions and contribute to shaping the future of prostate cancer care.
